Orexigen Receives Payments Totaling $22 Million from U.S. and Korean Partners (PR Newswire)

SAN DIEGO, Sept. 23, 2015 /PRNewswire/ — Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced receipt of the first of three potential $15 million anniversary milestone payments from Takeda Pharmaceuticals, Orexigen’s United States partner for Contrave ® (naltrexone HCl and bupropion HCl extended release). Two additional potential $15 million anniversary milestone payments are expected from Takeda in…

You may also like...